These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

142 related articles for article (PubMed ID: 31166063)

  • 41. Comparison of 3D and 2D tumor models reveals enhanced HER2 activation in 3D associated with an increased response to trastuzumab.
    Pickl M; Ries CH
    Oncogene; 2009 Jan; 28(3):461-8. PubMed ID: 18978815
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Additive effects of a prolactin receptor antagonist, G129R, and herceptin on inhibition of HER2-overexpressing breast cancer cells.
    Scotti ML; Langenheim JF; Tomblyn S; Springs AE; Chen WY
    Breast Cancer Res Treat; 2008 Sep; 111(2):241-50. PubMed ID: 17955362
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Dual PI3K/mTOR inhibitor BEZ235 exerts extensive antitumor activity in HER2-positive gastric cancer.
    Zhu Y; Tian T; Zou J; Wang Q; Li Z; Li Y; Liu X; Dong B; Li N; Gao J; Shen L
    BMC Cancer; 2015 Nov; 15():894. PubMed ID: 26560145
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Effective targeting of triple-negative breast cancer cells by PF-4942847, a novel oral inhibitor of Hsp 90.
    Mehta PP; Whalen P; Baxi SM; Kung PP; Yamazaki S; Yin MJ
    Clin Cancer Res; 2011 Aug; 17(16):5432-42. PubMed ID: 21715568
    [TBL] [Abstract][Full Text] [Related]  

  • 45. The tyrosine kinase inhibitor ZD1839 ("Iressa") inhibits HER2-driven signaling and suppresses the growth of HER2-overexpressing tumor cells.
    Moasser MM; Basso A; Averbuch SD; Rosen N
    Cancer Res; 2001 Oct; 61(19):7184-8. PubMed ID: 11585753
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Fasnall, a Selective FASN Inhibitor, Shows Potent Anti-tumor Activity in the MMTV-Neu Model of HER2(+) Breast Cancer.
    Alwarawrah Y; Hughes P; Loiselle D; Carlson DA; Darr DB; Jordan JL; Xiong J; Hunter LM; Dubois LG; Thompson JW; Kulkarni MM; Ratcliff AN; Kwiek JJ; Haystead TA
    Cell Chem Biol; 2016 Jun; 23(6):678-88. PubMed ID: 27265747
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Enhancing Antitumor Efficacy of Nucleoside Analog 5-Fluorodeoxyuridine on HER2-Overexpressing Breast Cancer by Affibody-Engineered DNA Nanoparticle.
    Zhang C; Han M; Zhang F; Yang X; Du J; Zhang H; Li W; Chen S
    Int J Nanomedicine; 2020; 15():885-900. PubMed ID: 32103944
    [TBL] [Abstract][Full Text] [Related]  

  • 48. A central role for HER3 in HER2-amplified breast cancer: implications for targeted therapy.
    Lee-Hoeflich ST; Crocker L; Yao E; Pham T; Munroe X; Hoeflich KP; Sliwkowski MX; Stern HM
    Cancer Res; 2008 Jul; 68(14):5878-87. PubMed ID: 18632642
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Small Molecular Leads Differentially Active Against HER2 Positive and Triple Negative Breast Cancer Cell Lines.
    Badran A; Atia-Tul-Wahab ; Fayyaz S; Baydoun E; Choudhary MI
    Med Chem; 2019; 15(7):738-742. PubMed ID: 30398120
    [TBL] [Abstract][Full Text] [Related]  

  • 50. A preclinical evaluation of the PI3K alpha/delta dominant inhibitor BAY 80-6946 in HER2-positive breast cancer models with acquired resistance to the HER2-targeted therapies trastuzumab and lapatinib.
    Elster N; Cremona M; Morgan C; Toomey S; Carr A; O'Grady A; Hennessy BT; Eustace AJ
    Breast Cancer Res Treat; 2015 Jan; 149(2):373-83. PubMed ID: 25528022
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Specific Drug Delivery to Cancer Cells with Double-Imprinted Nanoparticles against Epidermal Growth Factor Receptor.
    Canfarotta F; Lezina L; Guerreiro A; Czulak J; Petukhov A; Daks A; Smolinska-Kempisty K; Poma A; Piletsky S; Barlev NA
    Nano Lett; 2018 Aug; 18(8):4641-4646. PubMed ID: 29969563
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Design and development of PEGylated liposomal formulation of HER2 blocker Lapatinib for enhanced anticancer activity and diminished cardiotoxicity.
    Shrivastava R; Trivedi S; Singh PK; Asif M; Chourasia MK; Khanna A; Bhadauria S
    Biochem Biophys Res Commun; 2018 Sep; 503(2):677-683. PubMed ID: 29908185
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Effects of the EGFR/HER2 kinase inhibitor GW572016 on EGFR- and HER2-overexpressing breast cancer cell line proliferation, radiosensitization, and resistance.
    Zhou H; Kim YS; Peletier A; McCall W; Earp HS; Sartor CI
    Int J Radiat Oncol Biol Phys; 2004 Feb; 58(2):344-52. PubMed ID: 14751502
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Effect of multikinase inhibitors on caspase-independent cell death and DNA damage in HER2-overexpressing breast cancer cells.
    Seoane S; Montero JC; Ocaña A; Pandiella A
    J Natl Cancer Inst; 2010 Sep; 102(18):1432-46. PubMed ID: 20811002
    [TBL] [Abstract][Full Text] [Related]  

  • 55. DNA-affibody nanoparticles for inhibiting breast cancer cells overexpressing HER2.
    Zhang Y; Jiang S; Zhang D; Bai X; Hecht SM; Chen S
    Chem Commun (Camb); 2017 Jan; 53(3):573-576. PubMed ID: 27975087
    [TBL] [Abstract][Full Text] [Related]  

  • 56. HER2 (erbB-2)-targeted effects of the omega-3 polyunsaturated fatty acid, alpha-linolenic acid (ALA; 18:3n-3), in breast cancer cells: the "fat features" of the "Mediterranean diet" as an "anti-HER2 cocktail".
    Menéndez JA; Vázquez-Martín A; Ropero S; Colomer R; Lupu R
    Clin Transl Oncol; 2006 Nov; 8(11):812-20. PubMed ID: 17134970
    [TBL] [Abstract][Full Text] [Related]  

  • 57. A novel asymmetrical anti-HER2/CD3 bispecific antibody exhibits potent cytotoxicity for HER2-positive tumor cells.
    Yu S; Zhang J; Yan Y; Yao X; Fang L; Xiong H; Liu Y; Chu Q; Zhou P; Wu K
    J Exp Clin Cancer Res; 2019 Aug; 38(1):355. PubMed ID: 31412896
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Increased erbB3 promotes erbB2/neu-driven mammary tumor proliferation and co-targeting of erbB2/erbB3 receptors exhibits potent inhibitory effects on breast cancer cells.
    Lyu H; Huang J; Edgerton SM; Thor AD; He Z; Liu B
    Int J Clin Exp Pathol; 2015; 8(6):6143-56. PubMed ID: 26261492
    [TBL] [Abstract][Full Text] [Related]  

  • 59. [Effects of interferon-gamma on Her-2/neu expression and antitumor activity of 131I-Herceptin in breast cancer cell lines].
    Fan YX; Luo RC; Fang YX; Yan X; Lu CW
    Ai Zheng; 2006 Apr; 25(4):443-6. PubMed ID: 16613677
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Transformable peptide nanoparticles arrest HER2 signalling and cause cancer cell death in vivo.
    Zhang L; Jing D; Jiang N; Rojalin T; Baehr CM; Zhang D; Xiao W; Wu Y; Cong Z; Li JJ; Li Y; Wang L; Lam KS
    Nat Nanotechnol; 2020 Feb; 15(2):145-153. PubMed ID: 31988501
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.